Evidence map›Paper›PMID 40084969›Full record

ArticleUrology practice2025

Tumors in Solitary Kidneys Are Not All Equal: Outcomes of Partial Nephrectomy in High-Risk Cases.

Mark T Dawidek, Lina Posada Calderon, Juan Sebastian Arroyave Villada, Burcin A Ucpinar, Lennert Eismann, Stephen W Reese, Marc Ganz, Oguz Akin, Ed Reznik, Jonathan A Coleman and 2 more

Abstract read
In one paragraph

Article in Urology practice, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors.

Mark T DawidekUrology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0000-0003-2261-0857
Lina Posada CalderonUrology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.
Juan Sebastian Arroyave VilladaUrology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.
Burcin A UcpinarDepartment of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York.
Lennert EismannUrology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.
Stephen W ReeseUrology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.
Marc GanzUrology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.
Oguz AkinDepartment of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York.
Ed ReznikDepartment of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York.
Jonathan A ColemanUrology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.
A Ari HakimiUrology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.
Paul RussoUrology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
NCI NIH HHS P30 CA008748
6 · The paper itself

Abstract

introductionWhile partial nephrectomy remains the preferred treatment of tumors in solitary kidneys, there is a broad range of complexity to these cases. This retrospective study refines our understanding of renal and oncologic outcomes in high-risk cases of partial nephrectomy of the solitary kidney (PNSK).

methodsReview of our institutional database identified patients who underwent PNSK between 1990 and 2020. Cases were classified as high-risk PNSK based on having any of the following: clinical stage ≥ T3, RENAL (for radius, exophytic/endophytic, nearness of tumor to collecting system, anterior/posterior, location relative to polar line) nephrometry score ≥ 10, or multiple tumors suspicious for malignancies.

resultsOf the 124 cases included, 73 were classified as high-risk PNSK. The rate of high-grade perioperative complications was 32% among high-risk cases, compared with 12% among low-risk cases. The high-risk group recovered less of their baseline renal function compared with the low-risk group, although this gap narrowed with time, and the respective 5-year end-stage renal disease-free survivals were 89% and 100%. Baseline renal function, multifocal tumors, and intraoperative blood loss were predictors of long-term renal function. The 5-year local recurrence-free survival, cancer-specific survival, and overall survival rates in the high-risk group were 83%, 80%, and 77%, respectively.

conclusionsOutcomes of PNSK remain preferrable to end-stage renal disease in the highest-risk patients. Keys to optimization are meticulous preservation of normal parenchyma and a bloodless field. Longer ischemia time is tolerable to achieve these goals, although it may benefit from the application of renal hypothermia.

Indexed as

Kidney NeoplasmsNephrectomyPostoperative ComplicationsSolitary KidneyAdultAgedFemaleHumansMaleMiddle AgedRetrospective StudiesRisk AssessmentTreatment Outcomenephrectomyrenal cell carcinomarenal neoplasmssolitary kidney

Identifiers

PMID40084969
PMCPMC13435808

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.